Where Bioprocessing Outsourcers Stand On Capacity Concerns

By Kate Hammeke, VP of Market Research, Industry Standard Research (ISR) @ISRreports

Roughly four years ago, ISR added several capacity questions to our syndicated research on outsourced biologic drug substance manufacturing to understand how sponsors perceive available bioprocessing capacity. Our goal is to better understand if, and when, a capacity crunch may be coming. The first set of results from Q4 2018 relayed that roughly one-quarter of respondents’ companies (23%) were concerned there would not be sufficient available bioprocessing capacity to meet their organizations’ outsourced manufacturing needs. Forty percent of respondents in 2018 said No, their companies were not concerned about available bioprocessing capacity, and 37% said Maybe.